AiM Medical Robotics Inc. (AiM) has closed an $8.1 million Series A financing round led by IQ Capital (London) and 1540 Ventures (New York City), with participation from new and returning strategic investors.

“AiM is advancing neurosurgery with a robotic platform that integrates seamlessly into existing workflows and provides surgeons with real-time imaging to achieve safer, more precise, and more consistent outcomes for patients,” IQ Capital Partner Alex Wilson stated. “We’re excited to support the company as it moves toward first-in-human trials and clinical adoption.”

AiM’s technology enables surgeons to perform precise neurosurgical procedures directly within an MRI — addressing intraoperative shift and eliminating the need to move patients between operating rooms and imaging suites. The company’s neurosurgery system leverages real-time intraoperative MRI coupled with robotic guidance to ensure precise placement of neurostimulation leads for Parkinson’s disease patients. AiM’s robotic surgery platform also extends to a wide range of cranial procedures including biopsy, tumor ablation, and targeted intracranial delivery of novel therapeutics. This integration offers to make procedures faster, safer, and consistently more accurate while reducing patient risk and healthcare costs.

With an initial close in June 2025, the Series A totaled $8.1 million, including $3.75 million in notes converted into equity. The financing round attracted a broad investor base, with significant contributions from Worcester Polytechnic Institute (WPI); brain cancer impact investors such as the Sontag Innovation Fund (subsidiary of the Sontag Foundation) and Cancer Research Horizons (affiliate of Cancer Research U.K.); and prominent angel investor groups including New York Angels, Harvard Business School Alumni Angels, SWAN Impact Network, Angel Star Ventures, and Keiretsu Forum. To date, AiM has raised more than $11.3 million, further bolstered by significant federal grant support for the underlying technology.

“This investment marks the beginning of the next chapter for AiM as we prepare to bring our technology to patients,” AiM Medical Robotics Co-Founder/CEO Dr. Gregory Fischer said. “With first patient enrollment on the horizon, we are eager to demonstrate the profound clinical and commercial impact of AiM’s platform—not only in Parkinson’s disease but across a broad spectrum of cranial procedures including tumor biopsy, cancer and epilepsy ablation, and targeted intracranial drug delivery that will support the burgeoning field of stem cell and gene therapy.”

The Series A proceeds will fund AiM’s first-in-human clinical study, expand strategic partnerships, and accelerate product development and regulatory milestones.

AiM Medical Robotics is a privately held medical device company based in Worcester, Mass., developing next-generation MRI-compatible robotics for neurosurgery. AiM’s compact and portable robotic surgery platform integrates actuated instrument alignment into existing clinical workflows while enabling continuous, real-time visualization during surgery. Looking ahead, AiM plans to harness the power of artificial intelligence to enhance its robotic platform, creating an intelligent surgical ecosystem that can learn from real-world data, optimize workflows, and provide surgeons with predictive insights in real time. The company’s initial target market—DBS neurostimulator lead placement for conditions Parkinson’s disease, epilepsy, essential tremor, dystonia, and severe OCD—represents an estimated $7.9 billion opportunity.